Berberine Derivatives Suppress Cellular Proliferation and Tumorigenesis In Vitro in Human Non-Small-Cell Lung Cancer Cells
Open Access
- 13 June 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (12), 4218
- https://doi.org/10.3390/ijms21124218
Abstract
Lung cancer is the leading cause of death in the world, and the most common type of lung cancer is non-small-cell lung cancer (NSCLC), accounting for 85% of lung cancer. Patients with NSCLC, when detected, are mostly in a metastatic stage, and over half of patients diagnosed with NSCLC die within one year after diagnosis; the 5-year survival rate is 24%. However, in patients with metastatic NSCLC, the 5-year survival rate is 6%. Therefore, development of a new therapeutic agent or strategy is urgent for NSCLCs. Berberine has been illustrated to be a therapeutic agent of NSCLC. In the present study, we synthesized six derivatives of berberine, and the anti-NSCLC activity of these agents was examined. Some of them exert increasing proliferation inhibition comparing with berberine. Further studies demonstrated that two of the most effective agents, 9-O-decylberberrubine bromide (B6) and 9-O-dodecylberberrubine bromide (B7), performed cell cycle regulation, in-vitro tumorigenesis inhibition and autophagic flux blocking, but not induction of cellular apoptosis in NSCLC cells. Moreover, B6 and B7 were determined to be green fluorescent and could be penetrated and localized in cellular mitochondria. Herein, B6 and B7, the berberine derivatives we synthesized, revealed better anti-NSCLC activity with berberine and may be used as therapeutic candidates for the treatment of NSCLCs.Funding Information
- Ministry of Science and Technology, Taiwan (MOST 108-2314-B-705-001)
- Ditmanson Medical Foundation Chia-Yi Christian Hospital (R107-21)
This publication has 32 references indexed in Scilit:
- Berberine inhibits Smad and non-Smad signaling cascades and enhances autophagy against pulmonary fibrosisJournal of Molecular Medicine, 2015
- Berberine Induces Senescence of Human Glioblastoma Cells by Downregulating the EGFR–MEK–ERK Signaling PathwayMolecular Cancer Therapeutics, 2015
- Pharmacologic agents targeting autophagyJCI Insight, 2015
- Synthesis and anticancer activity of a novel series of 9-O-substituted berberine derivatives: A lipophilic substitute roleBioorganic & Medicinal Chemistry Letters, 2013
- Reversine, a 2,6-disubstituted Purine, as an Anti-cancer Agent in Differentiated and Undifferentiated Thyroid Cancer CellsPharmaceutical Research, 2012
- PTEN loss in the continuum of common cancers, rare syndromes and mouse modelsNature Reviews Cancer, 2011
- KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approachMolecular Carcinogenesis, 2010
- p53 cooperates berberine‐induced growth inhibition and apoptosis of non‐small cell human lung cancer cells in vitro and tumor xenograft growth in vivoMolecular Carcinogenesis, 2008
- Berberine suppresses MEK/ERK-dependent Egr-1 signaling pathway and inhibits vascular smooth muscle cell regrowth after in vitro mechanical injuryBiochemical Pharmacology, 2006
- Antimicrobial Activity of 9-O-Acyl- and 9-O-Alkylberberrubine DerivativesPlanta Medica, 2002